Is Johnson & Johnson (JNJ) overvalued? · P/E 17, rev $49.37B
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
This page asks whether Johnson & Johnson (JNJ) looks expensive on cached numbers — not a short thesis.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next JNJ 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the JNJ stock page for the full model, not this heading.
Not investment advice.